Floatz logo

Conestat Alfa

Hereditary Angioedema

CSL Behringprotein_peptidePhase 3Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Hereditary Angioedema cohort.

Asset / SponsorPhaseRating
Firazyr
Nang Kuang Pharmaceutical Co., Ltd.
Phase 4A
Firazyr
Nang Kuang Pharmaceutical Co., Ltd.
Phase 4A
Sebetralstat
KalVista Pharmaceuticals, Ltd.
Phase 4A
Berotralstat
BioCryst Pharmaceuticals
Phase 3A
Lanadelumab
Takeda
Phase 3A

View all 37 →

Same molecule, other indications

Conestat Alfa is also rated in:

common variable immunodeficiencyDormant
BB
Indicative ·
66 / 100
View asset →
infectious disease with sepsisDormant
B
Indicative ·
60 / 100
View asset →
injuryDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →